海南盈达润泽药业

Hainan Yingda Runze Pharmaceutical is a China-based biotechnology company focused on the discovery and development of innovative small molecule drugs. Founded in 2021 and headquartered in the Haikou National High-tech Zone, the company leverages the policy advantages of the Hainan Free Trade Port to accelerate its R&D processes. Its primary therapeutic focus lies in oncology and metabolic diseases, with a pipeline of candidates designed to address unmet medical needs through high selectivity and improved safety profiles. The company's lead program, YD-001, is currently in early-stage clinical trials for the treatment of solid tumors. Yingda Runze aims to establish itself as a leading innovative drug developer in the region by integrating internal research with strategic local partnerships.